Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: 2018

Transgene and Tasly Biopharmaceuticals conclude strategic agreements for the rights of TG6002 and TG1050 in Greater China

180710 – TG Tasly agreement PR

Published 10 July 2018
Categorized as 2018, Press release, TG1050, TG6002

Transgene’s Lead Oncolytic Virus Pexa-Vec Triggers Strong Anti-Tumor Immunity after Intravenous Administration

20180604 PR ASCO Pexa-vec neoadjuvant data EN

Published 4 June 2018
Categorized as 2018, Pexa-Vec, Press release

Transgene Announces Upcoming Investor Meetings

20180524 PR financial meetings Q2 18

Published 24 May 2018
Categorized as 2018, Press release

Combined General Meeting of May 23, 2018

20180523 TG AGM 2018 EN

Published 23 May 2018
Categorized as 2018, Press release

Single intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumor immunity

Alan Anthoney, et al. ASCO 2018, June 2018 – Abstract available on the ASCO website Download the poster here Poster Presentation

Published 17 May 2018
Categorized as -others, 2018, Pexa-Vec, Publication

Transgene to Present New Clinical Data on Oncolytic Virus Pexa-Vec at ASCO 2018

20180517 PR ASCO poster accepted EN

Published 17 May 2018
Categorized as 2018, Pexa-Vec, Press release

A multi-antigenic MVA vaccine increases efficacy of combination chemotherapy against Mycobacterium tuberculosis

Stephane Leung-Theung-Long, et al. PLOS One, May 2018 – Download the article Publication

Published 2 May 2018
Categorized as -others, 2018, Publication, TB Program

Availability of Preparatory Documents for the Combined General Meeting (Ordinary and Extraordinary Sessions) of May 23, 2018

20180502 MISE A DISPO AG – US

Published 2 May 2018
Categorized as 2018, Press release

€35.6 Million in Cash and Cash Equivalents as of March 31, 2018

20180426-Resultats-Q1-2018-EN

Published 26 April 2018
Categorized as 2018, Press release

Pseudocowpox: A next generation viral vector for cancer immunotherapy

Karolina Rittner, et al. AACR 2018, April 2018 – Abstract available on the AACR 2018 website Download the poster here Poster Presentation

Published 18 April 2018
Categorized as -others, 2018, Publication

Posts pagination

Newer posts Page 1 … Page 3 Page 4 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu